Related Experiment Video
Updated: Sep 9, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
[Primary biliary cholangitis-Update on diagnostics, risk stratification and new treatment options]
Toni Herta1,2, Thomas Berg3
1Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum und Campus Charité Mitte, Augustenburger Platz 1, 13353, Berlin, Deutschland. toni.herta@charite.de.
New peroxisome proliferator-activated receptor (PPAR) agonists offer improved treatment options for primary biliary cholangitis (PBC) patients who do not respond to ursodeoxycholic acid. These agents show promise in managing cholestasis and pruritus, enhancing patient care.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Acute Pancreatitis II: Clinical Manifestations and Management
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

